{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T11:54:38Z","timestamp":1775130878469,"version":"3.50.1"},"reference-count":24,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jocn-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Clinical Neuroscience"],"published-print":{"date-parts":[[2023,10]]},"DOI":"10.1016\/j.jocn.2023.08.022","type":"journal-article","created":{"date-parts":[[2023,9,3]],"date-time":"2023-09-03T10:59:15Z","timestamp":1693738755000},"page":"93-98","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["Long-term efficacy and safety of tacrolimus in young children with myasthenia gravis"],"prefix":"10.1016","volume":"116","author":[{"given":"Yan","family":"Zhang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Min","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Linmei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shuizhen","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wenhui","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.jocn.2023.08.022_b0005","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1111\/ene.13189","article-title":"Adequate tacrolimus concentration for myasthenia gravis treatment","volume":"24","author":"Kanai","year":"2017","journal-title":"Eur J Neurol"},{"issue":"5","key":"10.1016\/j.jocn.2023.08.022_b0010","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1159\/000510396","article-title":"Therapeutic and immunoregulatory effects of tacrolimus in patients with refractory generalized myasthenia gravis","volume":"83","author":"Wu","year":"2020","journal-title":"Eur Neurol"},{"issue":"5","key":"10.1016\/j.jocn.2023.08.022_b0015","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/S1474-4422(09)70063-8","article-title":"Autoimmune myasthenia gravis: emerging clinical and biological heterogeneity","volume":"8","author":"Meriggioli","year":"2009","journal-title":"Lancet Neurol"},{"issue":"4","key":"10.1016\/j.jocn.2023.08.022_b0020","doi-asserted-by":"crossref","first-page":"e939","DOI":"10.1542\/peds.2013-0814","article-title":"Clinical characteristics of pediatric myasthenia: a surveillance study","volume":"132","author":"VanderPluym","year":"2013","journal-title":"Pediatrics"},{"key":"10.1016\/j.jocn.2023.08.022_b0025","doi-asserted-by":"crossref","first-page":"53","DOI":"10.2174\/157488507779422437","article-title":"Tacrolimus treatment in myasthenia gravis","volume":"2","author":"Kawaguchi","year":"2007","journal-title":"Curr Drug Ther"},{"issue":"6","key":"10.1016\/j.jocn.2023.08.022_b0030","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1016\/j.nmd.2021.02.010","article-title":"Efficacy and safety of tacrolimus as long-term monotherapy for myasthenia gravis","volume":"31","author":"Itani","year":"2021","journal-title":"Neuromusc Disord"},{"issue":"4","key":"10.1016\/j.jocn.2023.08.022_b0035","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/j.intimp.2010.12.012","article-title":"Clinical efficacy and immunological impact of tacrolimus in Chinese patients with generalized myasthenia gravis","volume":"11","author":"Zhao","year":"2011","journal-title":"Int Immunopharmacol"},{"issue":"8","key":"10.1016\/j.jocn.2023.08.022_b0040","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1185\/030079904125004385","article-title":"Low-dose tacrolimus treatment in thymectomised and steroid-dependent myasthenia gravis","volume":"20","author":"Kawaguchi","year":"2004","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.jocn.2023.08.022_b0045","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.pediatrneurol.2017.08.014","article-title":"Tacrolimus improves symptoms of children with myasthenia gravis refractory to prednisone","volume":"77","author":"Liu","year":"2017","journal-title":"Pediatr Neurol"},{"issue":"2","key":"10.1016\/j.jocn.2023.08.022_b0050","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1111\/j.1600-0404.2006.00646.x","article-title":"Myasthenia gravis in children: a longitudinal study","volume":"114","author":"Ashraf","year":"2006","journal-title":"Acta Neurol Scand"},{"issue":"4","key":"10.1016\/j.jocn.2023.08.022_b0055","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1002\/mus.21195","article-title":"Juvenile myasthenia gravis","volume":"39","author":"Chiang","year":"2009","journal-title":"Muscle Nerve"},{"issue":"1","key":"10.1016\/j.jocn.2023.08.022_b0060","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1111\/nyas.13513","article-title":"The mouse passive-transfer model of MuSK myasthenia gravis: disrupted MuSK signaling causes synapse failure","volume":"1412","author":"Ghazanfari","year":"2018","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.jocn.2023.08.022_b0065","doi-asserted-by":"crossref","unstructured":"Randomised trial comparing tacrolimus (FK506) and cyclosporin in prevention of liver allograft rejection. European FK506 Multicentre Liver Study Group. Lancet. 1994 Aug 13;344(8920):423-8. 10.1016\/S0140-6736(94)91766-3.","DOI":"10.1016\/S0140-6736(94)91766-3"},{"issue":"1","key":"10.1016\/j.jocn.2023.08.022_b0070","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1002\/mus.10018","article-title":"Successful treatment of myasthenia gravis with tacrolimus","volume":"25","author":"Evoli","year":"2002","journal-title":"Muscle Nerve"},{"issue":"11","key":"10.1016\/j.jocn.2023.08.022_b0075","doi-asserted-by":"crossref","first-page":"743","DOI":"10.3389\/fneur.2020.00743","article-title":"Management of juvenile myasthenia gravis","volume":"24","author":"O'Connell","year":"2020","journal-title":"Front Neurol"},{"issue":"3","key":"10.1016\/j.jocn.2023.08.022_b0080","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.clineuro.2004.07.013","article-title":"Benefits of FK506 (tacrolimus) for residual, cyclosporin- and prednisone-resistant myasthenia gravis: one-year follow-up of an open-label study","volume":"107","author":"Ponseti","year":"2005","journal-title":"Clin Neurol Neurosurg"},{"issue":"8","key":"10.1016\/j.jocn.2023.08.022_b0085","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1016\/j.braindev.2008.08.016","article-title":"Benefits of FK 506 for refractory eye symptoms in a young child with ocular myasthenia gravis","volume":"31","author":"Ishigaki","year":"2009","journal-title":"Brain Dev"},{"key":"10.1016\/j.jocn.2023.08.022_b0090","unstructured":"Li JW, Fang F, Ren XT, Zhang WH, Yang XY, Ren CH, et al. [Clinical effect of tacrolimus in the treatment of myasthenia gravis in children]. Zhongguo Dang Dai Er Ke Za Zhi. 2020 Sep;22(9):964-969. Chinese. 10.7499\/j.issn.1008-8830.2004215."},{"issue":"13","key":"10.1016\/j.jocn.2023.08.022_b0095","article-title":"Long-term improvement in a Chinese cohort of glucocorticoid-resistant childhood-onset myasthenia gravis patients treated with tacrolimus","volume":"8","author":"Bi","year":"2022","journal-title":"Front Neurol"},{"issue":"7","key":"10.1016\/j.jocn.2023.08.022_b0100","doi-asserted-by":"crossref","first-page":"633","DOI":"10.3349\/ymj.2019.60.7.633","article-title":"Long-term safety and efficacy of tacrolimus in myasthenia gravis","volume":"60","author":"Kim","year":"2019","journal-title":"Yonsei Med J"},{"issue":"12","key":"10.1016\/j.jocn.2023.08.022_b0105","doi-asserted-by":"crossref","first-page":"2390","DOI":"10.1212\/01.WNL.0000147242.92691.71","article-title":"Etanercept treatment in corticosteroid-dependent myasthenia gravis","volume":"63","author":"Rowin","year":"2004","journal-title":"Neurology"},{"key":"10.1016\/j.jocn.2023.08.022_b0110","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1111\/j.1749-6632.2012.06817.x","article-title":"The myasthenia gravis\u2013specific activities of daily living profile","volume":"1274","author":"Muppidi","year":"2012","journal-title":"Ann N Y Acad Sci"},{"issue":"2","key":"10.1016\/j.jocn.2023.08.022_b0125","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1002\/mus.21462","article-title":"Factors associated with response to calcineurin inhibitors in myasthenia gravis","volume":"41","author":"Nagane","year":"2010","journal-title":"Muscle Nerve"},{"issue":"1","key":"10.1016\/j.jocn.2023.08.022_b0130","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.jns.2006.03.010","article-title":"Long-term therapeutic efficacy and safety of low-dose tacrolimus (FK506) for myasthenia gravis","volume":"247","author":"Tada","year":"2006","journal-title":"J Neurol Sci"}],"container-title":["Journal of Clinical Neuroscience"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0967586823002308?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0967586823002308?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T21:34:09Z","timestamp":1760823249000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0967586823002308"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10]]},"references-count":24,"alternative-id":["S0967586823002308"],"URL":"https:\/\/doi.org\/10.1016\/j.jocn.2023.08.022","relation":{},"ISSN":["0967-5868"],"issn-type":[{"value":"0967-5868","type":"print"}],"subject":[],"published":{"date-parts":[[2023,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Long-term efficacy and safety of tacrolimus in young children with myasthenia gravis","name":"articletitle","label":"Article Title"},{"value":"Journal of Clinical Neuroscience","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jocn.2023.08.022","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}